Jay Olson
Stock Analyst at Oppenheimer
(4.06)
# 539
Out of 5,090 analysts
243
Total ratings
45.13%
Success rate
14.25%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $600 → $650 | $577.30 | +12.59% | 12 | Nov 20, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $20 → $17 | $29.36 | -42.10% | 3 | Oct 22, 2025 | |
| IBIO iBio, Inc. | Initiates: Outperform | $5 | $1.20 | +316.67% | 1 | Oct 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $84 → $90 | $81.68 | +10.19% | 4 | Oct 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $21 → $30 | $6.40 | +368.75% | 3 | Sep 25, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $44 | $7.07 | +522.35% | 4 | Aug 11, 2025 | |
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $12.35 | +102.43% | 1 | Aug 4, 2025 | |
| ATAI Atai Beckley | Initiates: Outperform | $14 | $4.32 | +224.07% | 1 | Jul 29, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $97 → $115 | $247.99 | -53.63% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $27.44 | -19.83% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $11.07 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $4.18 | +1,455.02% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $1.71 | +3,701.17% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $2.07 | +528.02% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $79.64 | -5.83% | 9 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $56.90 | +58.17% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $19.96 | +110.42% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $44.36 | -25.61% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $9.61 | +316.23% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $3.32 | +502.41% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $6.39 | +369.48% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $181.30 | +40.65% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $102.52 | -20.02% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $27.46 | -63.58% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $38.55 | +257.98% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.85 | +107.79% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $329.89 | +15.19% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $155.51 | +40.83% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.42 | +395.87% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $4.28 | +320.56% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $8.66 | +1,054.73% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $56.88 | +67.02% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.20 | +1,983.33% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.73 | +420.23% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.58 | +31,545.57% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $14.60 | +43.84% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.24 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.68 | +375.11% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.74 | - | 3 | Jul 11, 2017 |
Madrigal Pharmaceuticals
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $577.30
Upside: +12.59%
Terns Pharmaceuticals
Oct 22, 2025
Maintains: Outperform
Price Target: $20 → $17
Current: $29.36
Upside: -42.10%
iBio, Inc.
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $1.20
Upside: +316.67%
Ionis Pharmaceuticals
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $81.68
Upside: +10.19%
Immuneering
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $6.40
Upside: +368.75%
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $7.07
Upside: +522.35%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $12.35
Upside: +102.43%
Atai Beckley
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $4.32
Upside: +224.07%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97 → $115
Current: $247.99
Upside: -53.63%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $27.44
Upside: -19.83%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $11.07
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $4.18
Upside: +1,455.02%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $1.71
Upside: +3,701.17%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $2.07
Upside: +528.02%
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $79.64
Upside: -5.83%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $56.90
Upside: +58.17%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $19.96
Upside: +110.42%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $44.36
Upside: -25.61%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $9.61
Upside: +316.23%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $3.32
Upside: +502.41%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $6.39
Upside: +369.48%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $181.30
Upside: +40.65%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $102.52
Upside: -20.02%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $27.46
Upside: -63.58%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $38.55
Upside: +257.98%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $3.85
Upside: +107.79%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $329.89
Upside: +15.19%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $155.51
Upside: +40.83%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.42
Upside: +395.87%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $4.28
Upside: +320.56%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $8.66
Upside: +1,054.73%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $56.88
Upside: +67.02%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.20
Upside: +1,983.33%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.73
Upside: +420.23%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.58
Upside: +31,545.57%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $14.60
Upside: +43.84%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.24
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.68
Upside: +375.11%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.74
Upside: -